A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)

NCT03239600 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The study is stopped for Portfolio prioritization.

Conditions

Autoimmune Diseases

Interventions

DRUG: GSK2618960 2 mg/kg
DRUG: Placebo
DRUG: Methotrexate

Sponsor

GlaxoSmithKline